je.st
news
Tag: samsung announces
Samsung announces new 14nm, octa-core SoC: Exynos 7 Octa 7870
2016-02-18 13:51:18| Extremetech
Samsung is bringing second-generation 14nm technology to its midrange smartphone devices this year, along with (we hope) a solid battery life boost. Hopefully manufacturers will use 14nm power savings to offer devices that prioritize battery life over shaving a few millimeters off the frame.
Tags: samsung
soc
announces
samsung announces
Small wonder: Samsung announces 2TB T3 portable SSD
2016-01-05 19:38:56| Extremetech
Samsung has announced a new portable USB SSD at CES 2016. The new T3 will pack up to 2TB of solid-state storage into a tiny form factor, while maintaining up to 450MB/s of performance.
Tags: small
samsung
portable
announces
Samsung Electronics announces GAIA security for Smart TVs
2015-12-30 04:00:39| Digital TV News
Samsung Electronics has announced GAIA, a three-layer security solution for its entire 2016 line up of Tizen-based Smart TVs. The service will give consumers protection across all areas of the Smart TV ecosystem, including services, software and hardware security.
Tags: security
electronics
samsung
smart
Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS (Infliximab), a Biosimilar of Remicade, in Korea
2015-12-07 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Samsung Bioepis Second Immunology Biosimilar Approved, to be Commercialized Under Partnership with Merck KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis Co., Ltd. has received approval of RENFLEXIS (infliximab), a biosimilar of the immunology medicine Remicade, by the Ministry of Food and Drug Safety (MFDS) in Korea. Merck will commercialize Samsung Bioepis RENFLEXIS in Korea as part of Mercks commercialization partnership with Samsung Bioepis to offer high-quality biosimilar alternatives to existing biologic medicines. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: korea
samsung
approval
receives
Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting
2015-11-05 14:43:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. One-Year Phase 3 Data for Investigational Biosimilar Candidates SB4, Enbrel (Etanercept) and SB2, Remicade (Infliximab) to be Presented for the First Time New Pivotal 24-Week Phase 3 Data for SB5, an Investigational Biosimilar of Humira (Adalimumab), to be Reported in Late-Breaking Presentation KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis will present new Phase 3 clinical data for three investigational immunology biosimilar candidates at the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) 2015 Annual Meeting in San Francisco, Nov. 7-11. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
present
meeting
annual
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] next »